Literature DB >> 28671346

Prothrombotic aspects of sickle cell disease.

E Sparkenbaugh1, R Pawlinski1.   

Abstract

Sickle cell disease (SCD) is a hematologic disorder caused by a well-characterized point mutation in the β-globin gene. Abnormal polymerization of hemoglobin tetramers results in the formation of sickle red blood cells that leads to vascular occlusions, hemolytic anemia, vascular inflammation and cumulative, multiple organ damage. Ongoing activation of coagulation is another hallmark of SCD. Recent studies strongly suggested that hypercoagulation in SCD is not just a secondary event but contributes directly to the disease pathophysiology. In this article we summarize mechanisms leading to the activation of coagulation, review data indicating direct contribution of coagulation to the pathology of SCD and, we discuss the anticoagulation as a possible treatment strategy to attenuate the disease progression.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  PAR; coagulation; sickle cell disease; thrombosis; tissue factor

Mesh:

Substances:

Year:  2017        PMID: 28671346     DOI: 10.1111/jth.13717

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

1.  Characterization and statistical modeling of glycosylation changes in sickle cell disease.

Authors:  Heather E Ashwood; Christopher Ashwood; Anna P Schmidt; Rebekah L Gundry; Karin M Hoffmeister; Waseem Q Anani
Journal:  Blood Adv       Date:  2021-03-09

Review 2.  Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics.

Authors:  Junaid Ansari; Felicity N E Gavins
Journal:  Am J Pathol       Date:  2019-04       Impact factor: 4.307

3.  Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

Authors:  Camille Faes; Anton Ilich; Amandine Sotiaux; Erica M Sparkenbaugh; Michael W Henderson; Laura Buczek; Joan D Beckman; Patrick Ellsworth; Denis F Noubouossie; Lantarima Bhoopat; Mark Piegore; Céline Renoux; Wolfgang Bergmeier; Yara Park; Kenneth I Ataga; Brian Cooley; Alisa S Wolberg; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2019-04-05       Impact factor: 22.113

Review 4.  Applied genomics in MPN presentation.

Authors:  Alison R Moliterno; Hannah Kaizer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.

Authors:  Alison R Moliterno; Yelena Z Ginzburg; Ronald Hoffman
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

6.  Venous Thromboembolism in Sickle Cell Disease is Associated with Neutrophilia.

Authors:  Jahnavi Gollamudi; Shashank Sarvepalli; Animesh Vadaparti Binf; Tara Alin; Jane A Little; Lalitha Nayak
Journal:  Hemoglobin       Date:  2021-02-15       Impact factor: 0.849

7.  A novel assay for studying the involvement of blood cells in whole blood thrombin generation.

Authors:  Jun Wan; Joke Konings; Qiuting Yan; Hilde Kelchtermans; Romy Kremers; Bas de Laat; Mark Roest
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

Review 8.  Emerging disease-modifying therapies for sickle cell disease.

Authors:  Marcus A Carden; Jane Little
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

9.  Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Chunsheng Chen; Tomasz Brzoska; Julia Nguyen; Shaobin Wang; Gregory M Vercellotti; Nigel S Key; Prithu Sundd; John D Belcher; Rafal Pawlinski
Journal:  Blood       Date:  2020-05-14       Impact factor: 25.476

10.  A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.

Authors:  Lewis L Hsu; Sharada Sarnaik; Suzan Williams; Carl Amilon; Jenny Wissmar; Anders Berggren
Journal:  Am J Hematol       Date:  2018-10-02       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.